1609201-07-1

Basic information

• Product Name: 3-(2-bromo-5-fluorophenyl)-2,2-dimethylpropanal
• Synonyms: 3-(2-bromo-5-fluorophenyl)-2,2-dimethylpropanal
• CAS NO: 1609201-07-1
• Molecular Weight: 259.118
• Mol File: 1609201-07-1.mol

Chemical Properties

• CAS DataBase Reference: 3-(2-bromo-5-fluorophenyl)-2,2-dimethylpropanal(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2-bromo-5-fluorophenyl)-2,2-dimethylpropanal(1609201-07-1)
• EPA Substance Registry System: 3-(2-bromo-5-fluorophenyl)-2,2-dimethylpropanal(1609201-07-1)

Safety Data

• Hazardous Substances Data: 1609201-07-1(Hazardous Substances Data)

Upstream product

• 112399-50-5 2-bromo-5-fluorobenzyl bromide 
• 78-84-2 isobutyraldehyde 

Downstream Products

• 1609201-06-0 2-[1-(2-bromo-5-fluorophenyl)-2-methylpropan-2-yl]-1,3-dioxolane 
• 1609201-05-9 2-[2-(1,3-dioxolan-2-yl)-2-methylpropyl]-4-fluorobenzenesulfonyl chloride 
• 1609201-04-8 methyl (1aR,7bS)-5-{2-[2-(1,3-dioxolan-2-yl)-2-methylpropyl]-4-fluorobenzenesulfonylamino}-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylate 
• 1609201-03-7 methyl (1aR,7bS)-5-[2-(2,2-dimethyl-3-oxopropyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa-[c]chromene-4-carboxylate 
• 1609200-65-8 (1aR,7bS)-5-[2-(3-diethylamino-2,2-dimethylpropyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylic acid 
• 1609201-02-6 methyl (1aR,7bS)-5-[2-(3-diethylamino-2,2-dimethylpropyl)-4-fluorobenzenesulfonylamino]-1,1a,2,7b-tetrahydrocyclopropa[c]chromene-4-carboxylate 

Relevant articles and documents

Intramolecular palladium(II)/(IV) catalysed C(sp3)-H arylation of tertiary aldehydes using a transient imine directing group

Palladium catalysed β-C(sp3)-H activation of tertiary aldehydes using a transient imine directing group enables intramolecular arylation to form substituted indane-aldehydes. A simple amine bearing a methyl ether (2-methoxyethan-1-amine) is the optimal TDG to promote C-H activation and reaction with an unactivated proximal C-Br bond. Substituent effects are studied in the preparation of various derivatives. Preliminary mechanistic studies identify a reversible C-H activation, product inhibition and suggest that oxidative addition is the turnover limiting step.

TRICYCLIC COMPOUNDS FOR USE IN THE TREATMENT AND/OR CONTROL OF OBESITY

The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided. The compounds are contemplated to have activity against me